The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing synovial inflammation and joint destruction.
• Current disease-modifying antirheumatic drugs (DMARDs) have limitations in efficacy and safety.
• Novel therapeutic targets are needed to address unmet clinical needs in RA management.

Purpose of the Study:

• To review the role of Cellular Communication Network factor 3 (CCN3) in rheumatoid arthritis.
• To examine CCN3's expression, functions, and signaling pathways in RA.
• To explore CCN3 as a potential therapeutic target for RA.

Main Methods:

• Comprehensive literature review of studies on CCN3 in RA.
• Analysis of CCN3 expression patterns in normal and RA synovium and circulation.
• Examination of CCN3's functional effects on inflammatory cells, synoviocytes, and joint tissues.
• Investigation of CCN3's interactions with key signaling pathways implicated in RA pathogenesis.

Main Results:

• CCN3 expression is low in normal synovium but significantly elevated in RA synovium and circulation.
• Elevated CCN3 levels correlate with RA disease activity, anti-CCP antibody titers, and IL-6 levels.
• CCN3 influences inflammatory cell recruitment, fibroblast-like synoviocyte activation and senescence, ECM remodeling, cartilage degradation, and osteoclastogenesis.
• CCN3 interacts with multiple RA-relevant signaling pathways including NF-κB, Wnt/β-catenin, BMP/Smad, PI3K/Akt/mTOR, IL-6/JAK/STAT, Notch, and MAPK.

Conclusions:

• CCN3 plays a significant role in the pathogenesis of rheumatoid arthritis.
• CCN3's multifaceted involvement in inflammation, joint destruction, and signaling pathways highlights its therapeutic potential.
• Targeting CCN3 represents a promising strategy for developing novel RA treatments in preclinical research.